Abstract
This is the third part of a review on the transport of drugs across the blood-brain barrier. In the first two parts, the anatomical and physiological aspects and the various techniques that can be used to study blood-brain transport have been discussed and reviewed. This third part focuses specifically on the mechanisms that are involved in drug transport across the blood-brain barrier. In addition, the opportunities to improve drug transport into the brain will be reviewed. Emphasis is on the transport of peptides.
Similar content being viewed by others
References
Van Bree JBMM, De Boer, AG, Danhof M, Breimer DD. Drug transport across the blood-brain barrier. I. Anatomical and physiological aspects. Pharm Weekbl [Sci] 1992;14(5):305–10.
Van Bree JBMM, De Boer AG, Danhof M, Breimer DD. Drug transport across the blood-brain barrier. II. Experimental techniques to study drug transport. Pharm Weekbl [Sci] 1992;14(6):338–48.
Stein WD. The movement of molecules across cell membranes. New York: Academic Press, 1971:369.
Brodie BB, Kurz H, Shanker LS. The importance of dissociation constant and lipid-solubility in influencing the passage of drugs into the cerebrospinal fluid. J Pharmacol Exp Ther 1960;130:20–5.
Oldendorf WH. Lipid solubility and penetration of the blood-brain barrier. Proc Soc Exp Biol Med 1974;147:813–6.
Rapoport SI, Ohno K, Pettigrew KD. Drug entry into the brain. Brain Res 1979;172:354–9.
Levin VA. Relationship of octanol/water partition coefficient and molecular weight of rat brain capillary permeability. J Med Chem 1980;23:682–4.
Oldendorf WH. Blood-brain barrier permeability to drugs. Ann Rev Pharmacol 1974;14:239–48.
Pardridge WM. Carrier-mediated transport of thyroid hormones through the rat blood-brain barrier: primary role of albumin bound hormone. Endocrinology 1979;105:605–12.
Jones DR, Hall SD, Jackson EK, Branch RA, Wilkinson GR. Brain uptake of benzodiazepines: effects of lipophilicity and plasma protein binding. J Pharmacol Exp Ther 1988;245:816–22.
Pardridge WM, Landaw EM. Tracer kinetic model of blood-brain barrier transport of plasma protein-bound ligands. J Clin Invest 1974;74:745–52.
Pardridge WM. Plasma protein-mediated transport of steroid and thyroid hormones. Am J Physiol 1987;252:E157–64.
Forker EL, Luxon BA. Albumin-mediated transport of rose bengal: kinetics of reactions at the cell surface. J Clin Invest 1983;72:1764–71.
Rehfeld JF. Localisation of gastrins to neuro- and adenohypophysis. Nature 1978;271:771–3.
Muller JE, Sraus E, Yalow RS. Cholecystokinin and its COOH-terminal octapeptide in pig brain. Proc Natl Acad Sci USA 1977;74:3035–7.
Giachetti A, Said SI, Reynolds RC, Koniges FC. Vasoactive intestinal polypeptide in brain: localisation in and release from isolated nerve terminals. Proc Natl Acad Sci USA 1977;74:3424–8.
Mutt V, Carlquist M, Tatemoto K. Secretin-like bioactivity in extracts of porcine brain. Life Sci 1979;25:1703–8.
Havrankova J, Schmechel D, Brownstein M. Identification of insulin in rat brain. Proc Natl Acad Sci USA 1978;75:5737–41.
Greven HM, De Wied D. Neuropeptides and behaviour. In: Eberle A, Geiger R, Wieland T, eds. Perspectives in peptide chemistry. Basel: Karger, 1981:358–71.
Kovacs GL, Veldhuis HD, Versteeg DHG, De Wied D. Facilitation of avoidance behaviour by vasopressin fragments microinjected into limbic-midbrain structures. Brain Res 1986;371:17–24.
Meisenberg, G, Simmons WH. Centrally mediated effects of neurohypophyseal hormones. Neurosci Behav Rev 1983;7:263–80.
Cornford EM, Braun LD, Crane PD, Oldendorf WH. Blood-brain barrier restriction of peptides and the low uptake of enkephalins. Endocrinology 1978;103:1297–303.
Houghten RA, Swann RW, Li CH.β-Endorphin: stability, clearance behaviour and entry into the central nervous system after intravenous injection of the tritiated peptide in rats and rabbits. Proc Natl Acad Sci USA 1980;77:4588–91.
Ang VTY, Jenkins JS. Blood-cerebrospinal fluid barrier to arginine-vasopressin, desmopressin and desglycinamide arginine-vasopressin in the dog. J Endocrinol 1982;93:319–25.
Zhu XG, Greeley GH, Lewis BG, Lilja P, Thompson JC. Blood-cerebrospinal fluid barrier to CCK and effect of centrally administered bombesin on release of brain CCK. J Neurosci Res 1986;15:393–403.
Levin ER, Frank HJL, Weber MA, Ismail M, Mills S. Studies on the penetration of the blood-brain barrier by atrial natriuretic factor. Biochem Biophys Res Commun 1987;147:1226–31.
Hersh, LB, McKelvy JF. An aminopeptidase from bovine brain which catalyses the hydrolysis of enkephalin. J Neurochem 1981;36:171–8.
Verhoef JC, Scholtens H, Vergeer EG, Witter A. Des-tyrgamma-endorphin (DyγE) and des-enkephalin-gamma-endorphin (DEγE): plasma profile and brain uptake after systemic administration in the rat. Peptides 1985;6:467–74.
Riekkinnen P, Legros JJ, Sennef C, Jolkkonen J, Smitz S, Soininen H. Penetration of DGAVP (Org 5667) across the blood-brain barrier in human subjects. Peptides 1987; 8:261–5.
Collins JM, Dedrick RL. Distributed model for drug delivery to cerebrospinal fluid and brain tissue. Am J Physiol 1983;245:R303–10.
Grundy HF. Circulation of cerebrospinal fluid in the spinal region of the cat. J Physiol 1962;163:457–65.
Rall DP, Oppelt WW, Patlak CS. Extracellular space of brain as determined by infusion of inulin from the ventricular system. Life Sci 1962;2:43–8.
Kastin AJ, Nissen Ch, Coy DH. Permeability of blood-brain barrier to DSIP peptides. Pharmacol Biochem Behav 1981;15:955–9.
Greig NH, Soncrant TT, Wozniak KM, Rapoport SI. Plasma and tissue pharmacokinetics of human interferon-α in the rat after its intravenous administration. J Pharmacol Exp Ther 1988;245:574–80.
Van Bree JBMM, Tio S, De Boer AG, Danhof M, Verhoef JC, Breimer DD. Transport of desglycinamide-arginine vasopressin across the blood-brain barrier in rats as evaluated by the unit impulse response methodology. Pharm Res 1990;7(3):292–307.
Banks WA, Kastin AJ. Peptides and the blood-brain barrier: lipophilicity as a predictor of permeability. Brain Res Bull 1985;15:287–92.
Van Bree JBMM, De Boer AG, Danhof M, Ginsel LA, Breimer DD. Characterization of anin vitro blood-brain barrier: effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs. J Pharmacol Exp Ther 1988;247(3):1233–9.
Van Bree JBMM, De Boer AG, Verhoef JC, Danhof M, Breimer DD. Transport of vasopressin fragments across the blood-brain barrier:in vitro studies using monolayer cultures of bovine brain endothelial cells. J Pharmacol Exp Ther 1989;249:901–5.
Fishman JB, Rubin JB, Handrahan JV, Connor JR, Fine RE. Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J Neurosci Res 1987;18:299–304.
Frank HJL, Pardridge WM, Morris WL, Rosenfeld RG, Choi TB. Binding and internalisation of insulin and insulin-like growth factor by isolated brain microvessels. Diabetes 1986; 35:654–61.
Banks WA, Kastin AJ. A brain to blood carrier-mediated transport system for small,N-tyrosinated peptides. Pharmacol Biochem Behav 1984;21:943–6.
Banks WA, Kastin AJ, Horvath A, Michals EA. Carrier-mediated transport of vasopressin across the blood-brain barrier of the mouse. J Neurosci Res 1987;18:326–32.
Banks WA, Kastin AJ. Inhibition of the brain to blood transport system for enkephalins and Tyr-MIF-1 in mice addicted or genetically predisposed to drinking ethanol. Alcohol 1989;6:53–7.
Zlokovic BV, Segal MB, Begley DJ. Permeability of the isolated choroid plexus of the sheep to thyrotropin releasing hormone. In: Yudelevich DL, Mann GE, eds. Carriermediated transport of solutes from brain to tissue. London: Longmans, 1985:307–12.
Ommaya A. A subcutaneous reservoir and pump for sterile access to ventricular cerebrospinal fluid. Lancet 1963;2:983–4.
Barranger JA, Rapoport SI, Fredericks WR, Pentchev PG, MacDermot KD, Steusing JK, et al. Modification of the blood-brain barrier: increased concentration and fate of enzymes entering the brain. Proc Natl Acad Sci 1979;76:481–5.
Rapoport SI, Fredericks WR, Ohno K, Pettigrew KD. Quantitative aspects of reversible osmotic opening of the blood-brain barrier. Am J Physiol 1980;238:R421–31.
Neuwelt EA, Barnett PA, Hellstrom KE, Beaumier P, McCormick CI, Weigel RM. Delivery of melanoma-associated immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption. Cancer Res 1988;48:4725–9.
Neuwelt EA, Rapoport SI. Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors. Fed Proc 1984;43:214–9.
Hiesmayr M, Dirnberger H, Aloy A, Heimberger K, Horaczek A, Brandstatter B, et al. Haemodynamic effects of a osmotic bolus for the reversible opening of the blood-brain barrier. Schweiz Med Wochenschr 1987;117:450–4.
Warnke PC, Blasberg RG, Groothuis DR. The effect of hyperosmotic blood-brain barrier disruption on blood to tissue transport in ENU-induced gliomas. Ann Neurol 1987;22:300–5.
Suzuki M, Iwasaki Y, Yamamoto T, Konno H, Kudo H. Sequelae of osmotic blood-brain barrier opening in rats. J Neurosurg 1988;69:421–8.
Gross PM, Teasdale GM, Graham DI, Angerson WJ, Harper AM. Intra-arterial histamine increases blood-brain transport in rats. Am J Physiol 1092;243:H307–17.
Domer FR, Boertje SB, Bing EG, Reddin I. Histamine and acetylcholine-induced changes in the permeability of the blood-brain barrier of normotensive and spontaneously hypertensive rats. Neuropharmacology 1983;22:615–9.
Banks WA, Kastin AJ. Aluminium increases permeability of the blood-brain barrier to labelled DSIP andβ-endorphin: possible implications for senile and dialysis dementia. Lancet 1983;1:1227–9.
Raymond, JJ, Robertson DM, Dinsdale HB, Nag S. Pharmacological modification of blood-brain barrier permeability following a cold lesion. Can J Neurol Sci 1984;11:447–51.
Gulati A, Nath C, Shanker K, Srimal RC. Effect of alcohols on the permeability of blood-brain barrier. Pharmacol Res Commun 1985;17:85–93.
Nishihata T, Cho R, Kato J, Kamada A. Effect of salicylate on the uptake of cefmetazole into mice brain. Pharm Res 1985;5:243–5.
Zapulla RA, Spigelman MK, Omsberg E, Rosen JJ, Malis LI, Holland JF. EEG consequences of sodium dehydrocholate-induced blood-brain barrier disruption. Part 1. Neurosurgery 1985;16:630–8.
Spigelman MK, Zappulla RA, Strauchen JA, Feuer EJ, Johnson J, Goldsmith SJ, et al. Etoposide induced blood-brain barrier disruption in rats: duration of opening and histological sequelae. Cancer Res 1986;46:1453–7.
Raymond JJ, Robertson DM, Dinsdale HB. Pharmacological modification of bradykinin induced breakdown of the blood-brain barrier. Can J Neurol Sci 1986;13:214–20.
Strausbaugh LJ. Intracarotid infusions of protamine sulfate disrupt the blood-brain barrier of rabbits. Brain Res 1987; 409:221–6.
Sharma HS. Effect of captopril on blood-brain barrier permeability and cerebral blood flow in normotensive rats. Neuropharmacology 1987;26:85–92.
Sokrab TEO, Johansson BB, Kalimo H, Olsson Y. A transient hypertensive opening of the blood-brain barrier can lead to brain damage. Acta Neuropathol 1988;75:557–65.
Baba M, Oishi R, Saeki K. Enhancement of blood-brain barrier permeability to sodium fluorescein by stimulation ofμ opioid receptors in mice. Arch Pharmacol 1988;337:423–8.
Greig NH. Drug delivery to the brain by blood-brain barrier circumvention and drug modification. In: Neuwelt EA, ed. Implications of the blood-brain barrier and its manipulation. New York: Plenum, 1989:311–67. (Basic science aspects; vol. 1.)
Bodor N, Shek E, Higuchi T. Delivery of a quaternary pyridinium salt across the blood-brain barrier as its dihydropyridine derivative. Science 1975;190:155–6.
Nutt JG, Woodward WR, Hammerstad JP. The on-off phenomenon in Parkinson's disease: relation to levodopa and transport. N Engl J Med 1984;310:483–8.
Partridge WM. Peptide drug delivery to the brain. New York: Raven Press, 1991.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Van Bree, J.B.M.M., De Boer, A.G., Danhof, M. et al. Drug transport across the blood-brain barrier. Pharm World Sci 15 (Suppl 1), 2–9 (1993). https://doi.org/10.1007/BF02116163
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02116163